

In the Claims

1-59 (canceled).

60 (currently amended). A composition of matter comprising:

- a) an isolated polypeptide comprising:
 - i) SEQ ID NO: 4;
 - ii) SEQ ID NO: 6; or
 - iii) a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence;
- b) an isolated polynucleotide:
 - A) encoding a polypeptide, said polypeptide comprising:
 - i) SEQ ID NO: 4;
 - ii) SEQ ID NO: 6; or
 - iii) a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence;
 - B) comprising SEQ ID NO: 3; or
 - C) comprising SEQ ID NO: 5;
- c) a vector comprising a polynucleotide:
 - A) encoding a polypeptide comprising:
 - i) SEQ ID NO: 4;
 - ii) SEQ ID NO: 6; or

- iii) a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence;
- B) comprising SEQ ID NO: 3; or
- C) comprising SEQ ID NO: 5; or
- d) an isolated host cell transformed or transfected with an expression vector comprising a polynucleotide:
 - A) encoding a polypeptide comprising:
 - i) SEQ ID NO: 4;
 - ii) SEQ ID NO: 6; or
 - iii) a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence;
 - B) comprising SEQ ID NO: 3; or
 - C) comprising SEQ ID NO: 5; ~~or~~
- e) ~~an isolated antibody that binds to a polypeptide comprising:~~
 - i) ~~SEQ ID NO: 4; or~~
 - ii) ~~SEQ ID NO: 6.~~

61 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a polypeptide that is post-translationally modified.

62 (previously presented). The composition of matter according to claim 61, wherein said composition of matter is a polypeptide that is glycosylated.

63 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a polypeptide that is PEGylated.

64-66 (canceled).

67. (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polypeptide comprising SEQ ID NO: 4.

68. (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polypeptide comprising SEQ ID NO: 6.

69. (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polypeptide comprising a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

70 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polynucleotide encoding a polypeptide comprising SEQ ID NO: 4.

71 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polynucleotide encoding a polypeptide comprising SEQ ID NO: 6.

72 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polynucleotide encoding a polypeptide comprising a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a

multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

73 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polynucleotide comprising SEQ ID NO: 3.

74 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is an isolated polynucleotide comprising SEQ ID NO: 5.

75 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a vector comprising a polynucleotide, said polynucleotide encoding a polypeptide comprising SEQ ID NO: 4.

76 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a vector comprising a polynucleotide, said polynucleotide encoding a polypeptide comprising SEQ ID NO: 6.

77 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a vector comprising a polynucleotide, said polynucleotide encoding a polypeptide comprising a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

78 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a vector comprising SEQ ID NO: 3.

79 (previously presented). The composition of matter according to claim 60, wherein said composition of matter is a vector comprising SEQ ID NO: 5.

80 (currently amended). The composition of matter according to claim 60, wherein said composition of matter is ~~a~~ an isolated host cell transformed or transfected with an expression vector comprising a polynucleotide encoding SEQ ID NO: 4.

81 (currently amended). The composition of matter according to claim 60, wherein said composition of matter is an isolated host cell transformed or transfected with an expression vector comprising a polynucleotide encoding SEQ ID NO: 6.

82 (currently amended). The composition of matter according to claim 60, wherein said composition of matter is ~~a~~ an isolated host cell transformed or transfected with an expression vector comprising a polynucleotide encoding a polypeptide comprising a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

83 (currently amended). The composition of matter according to claim 60, wherein said composition of matter is ~~a~~ an isolated host cell transformed or transfected with an expression vector comprising SEQ ID NO: 3.

84 (currently amended). The composition of matter according to claim 60, wherein said composition of matter is ~~a~~ an isolated host cell transformed or transfected with an expression vector comprising SEQ ID NO: 5.

85-86 (canceled).

87 (previously presented). A process for preparing a polypeptide comprising culturing a transformed or transfected host cell under conditions allowing or promoting expression of a polypeptide, said host cell comprising:

- a) a polynucleotide encoding a polypeptide selected from:
 - i) SEQ ID NO: 4;
 - ii) SEQ ID NO: 6;
 - iii) a fusion protein comprising SEQ ID NO: 4 or SEQ ID NO: 6 fused to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence;
- b) a polynucleotide comprising SEQ ID NO: 3; or
- c) a polynucleotide comprising SEQ ID NO: 5.

88 (previously presented). The process according to claim 87, further comprising purifying the polypeptide.

89 (previously presented). The process according to claim 88, further comprising formulating the polypeptide into a composition.

90 (previously presented). A method of inhibiting TNF- α release by monocytes comprising contacting monocytes with a composition comprising a carrier and a polypeptide comprising SEQ ID NO: 4 or SEQ ID NO: 6.

91 (previously presented). The method according to claim 90, wherein said polypeptide is SEQ ID NO: 6.

92 (previously presented). The method according to claim 90, wherein said polypeptide comprises SEQ ID NO: 4.